Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response

OncoImmunology

Volumn 1, Issue 9, 2012, Pages 1546-1556

  Johnson, Laura E ^a   Frye, Thomas P ^a   McNeel, Douglas G ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

DNA vaccine; Epitopes; Prostate cancer; Prostatic acid phosphatase; Rat; RT1.A1; Xenoantigen

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; AMINO ACID; CD8 ANTIGEN; CYTOKINE; DNA VACCINE; EPITOPE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG CROSS REACTIVITY; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PEPTIDE LIBRARY; PRIORITY JOURNAL; PROSTATE CANCER; RAT; SPLEEN CELL; T LYMPHOCYTE;

EID: 84886944765     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22564     Document Type: Article

References (30)

1. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al.; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294.
2. Johnson LE, Frye TP, Chinnasamy N, Chinnasamy D, McNeel DG. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. Cancer Immunol Immunother 2007; 56:885-95; PMID:17102977; http://dx.doi.org/10.1007/s00262-006-0241-8.
3. Johnson LE, Frye TP, Arnot AR, Marquette C, Couture LA, Gendron-Fitzpatrick A, et al. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine 2006; 24:293-303; PMID:16115700; http://dx.doi.org/10.1016/j.vaccine.2005.07.074.
4. McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 2009; 27:4047-54; PMID:19636017; http://dx.doi.org/10.1200/JCO.2008.19.9968.
5. Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, McNeel DG. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother 2010; 33:639-47; PMID:20551832; http://dx.doi.org/10.1097/CJI.0b013e3181dda23e.
6. Gold JS, Ferrone CR, Guevara-Patiño JA, Hawkins WG, Dyall R, Engelhorn ME, et al. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol 2003; 170:5188-94; PMID:12734366.
7. Bowne WB, Srinivasan R, Wolchok JD, Hawkins WG, Blachere NE, Dyall R, et al. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 1999; 190:1717-22; PMID:10587362; http://dx.doi.org/10.1084/jem.190.11.1717.
8. Naftzger C, Takechi Y, Kohda H, Hara I, Vijayasaradhi S, Houghton AN. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci U S A 1996; 93:14809-14; PMID:8962137; http://dx.doi.org/10.1073/pnas.93.25.14809.
9. Hawkins WG, Gold JS, Dyall R, Wolchok JD, Hoos A, Bowne WB, et al. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery 2000; 128:273- 80; PMID:10923004; http://dx.doi.org/10.1067/msy.2000.107421.
10. Yuan J, Ku GY, Gallardo HF, Orlandi F, Manukian G, Rasalan TS, et al. Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun 2009; 9:5; PMID:19496531.
11. Wolchok JD, Yuan J, Houghton AN, Gallardo HF, Rasalan TS, Wang J, et al. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol Ther 2007; 15:2044-50; PMID:17726460; http://dx.doi.org/10.1038/sj.mt.6300290.
12. Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003; 9:1284-90; PMID:12684396.
13. Gregor PD, Wolchok JD, Turaga V, Latouche JB, Sadelain M, Bacich D, et al. Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. Int J Cancer 2005; 116:415- 21; PMID:15800947; http://dx.doi.org/10.1002/ijc.21014.
14. Slovin S, Gregor P, Wolchok J, Pedraza A, Orlandi F, Jefferson M, et al. A xenogeneic PSMA DNA vaccine for patients with non-castrate metastatic (NCMPC) and castrate metastatic prostate cancer (CMPC)-A phase I trial of proof of principle. J Clin Oncol 2007; 25:3073.
15. Hassan MI, Aijaz A, Ahmad F. Structural and functional analysis of human prostatic acid phosphatase. Expert Rev Anticancer Ther 2010; 10:1055- 68; PMID:20645695; http://dx.doi.org/10.1586/era.10.46.
16. Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol 1997; 159:3113-7; PMID:9317107.
17. Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 2001; 167:7150-6; PMID:11739538.
18. Reizis B, Mor F, Eisenstein M, Schild H, Stefanoviç S, Rammensee HG, et al. The peptide binding specificity of the MHC class II I-A molecule of the Lewis rat, RT1. BI. Int Immunol 1996; 8:1825-32; PMID:8982766; http://dx.doi.org/10.1093/intimm/8.12.1825.
19. Reizis B, Schild H, Stefanovic S, Mor F, Rammensee H, Cohen IR. Peptide binding motifs of the MHC class I molecules (RT1.Al) of the Lewis rat. Immunogenetics 1997; 45:278-9; PMID:9002449; http://dx.doi.org/10.1007/s002510050204.
20. Mincheff M, Zoubak S, Makogonenko Y. Immune responses against PSMA after gene-based vaccination for immunotherapy-A: results from immunizations in animals. Cancer Gene Ther 2006; 13:436- 44; PMID:16276349; http://dx.doi.org/10.1038/sj.cgt.7700914.
21. Gregor PD, Wolchok JD, Ferrone CR, Buchinshky H, Guevara-Patiño JA, Perales MA, et al. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine 2004; 22:1700-8; PMID:15068853; http://dx.doi.org/10.1016/j.vaccine.2003.10.048.
22. Smith HA, McNeel DG. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitopespecific cytolytic T cells. J Immunother 2011; 34:569- 80; PMID:21904219; http://dx.doi.org/10.1097/CJI.0b013e31822b5b1d.
23. Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, et al. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother 2010; 59:943-53; PMID:20140431; http://dx.doi.org/10.1007/s00262-010-0820-6.
24. Peshwa MV, Shi JD, Ruegg C, Laus R, van Schooten WC. Induction of prostate tumorspecific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 1998; 36:129- 38; PMID:9655265; http://dx.doi.org/10.1002/(SICI)1097-0045(19980701)36:2<129::AIDPROS8>3.0.CO;2-D.
25. Harada M, Matsueda S, Yao A, Ogata R, Noguchi M, Itoh K. Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients. Oncol Rep 2004; 12:601-7; PMID:15289844.
26. Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, et al. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Cancer Res 2005; 65:6435-42; PMID:16024648; http://dx.doi.org/10.1158/0008-5472.CAN-05-0133.
27. Matsueda S, Takedatsu H, Yao A, Tanaka M, Noguchi M, Itoh K, et al. Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles. Clin Cancer Res 2005; 11:6933-43; PMID:16203785; http://dx.doi.org/10.1158/1078-0432.CCR-05-0682.
28. Johnson LE, McNeel DG. Identification of prostatic acid phosphatase (PAP) specific HLA-DR1- restricted T-cell epitopes. Prostate 2012; 72:730- 40; PMID:22529020; http://dx.doi.org/10.1002/ pros.21477.
29. Choe BK, Pontes EJ, Bloink S, Rose NR. Human prostatic acid phosphatases: I. Isolation. Arch Androl 1978; 1:221-6; PMID:83814; http://dx.doi.org/10.3109/01485017808988340.
30. Caraher EM, Parenteau M, Gruber H, Scott FW. Flow cytometric analysis of intracellular IFNgamma, IL-4 and IL-10 in CD3(+)4(+) T-cells from rat spleen. J Immunol Methods 2000; 244:29-40; PMID:11033016; http://dx.doi.org/10.1016/S0022-1759(00)00249-0.